Patrys is a publicly-listed company on the Australian Securities Exchange (ASX:PAB).  Our principal focus is on the development of antibody therapies for major market opportunities in the oncology area.  

Patrys has two technology platforms: IgM monoclonal antibodies and suite of nuclear penetrating antibodies for cancer therapy.